Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's drugs
Biotech
Fosun pays $60M for option on AriBio’s phase 3 Alzheimer’s asset
Fosun Pharma secured the chance to expand its rights to the asset in exchange for a further $80 million.
Nick Paul Taylor
May 13, 2026 9:15am
Galimedix's oral Alzheimer's candidate clears ph. 1 safety test
Sep 12, 2025 11:11am
Prothena Alzheimer's trial hit by ARIA showstopper
Aug 28, 2025 6:48am
Denali Alzheimer's antibody clears plaques without ARIA in mice
Aug 7, 2025 2:00pm
Alzheon Alzheimer's drug knocked down in pivotal APOLLOE4 bout
Apr 10, 2025 8:48am
AbbVie inks $1.4B Aliada buyout to land ex-J&J Alzheimer's drug
Oct 28, 2024 10:00am
